Evaluation of embryotoxicity for major components of herbal extracts using the chick embryonic heart micromass and mouse D3 embryonic stem cell systems

Reproductive Toxicology

Volumn 59, Issue , 2016, Pages 117-127

  Mohammed, Omar J ^a   Latif, Muhammad Liaque ^a   Pratten, Margaret K ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

6 gingerol; Chick embryonic cardiomyocytes; Ginkgolide A; Ginkgolide B; Ginsenoside Rg1; Herbal medicines; Micromass; Mouse D3 embryonic stem cells

Indexed keywords

(6) GINGEROL; ALPHA ACTININ; GINKGOLIDE A; GINKGOLIDE B; GINSENOSIDE RG 1; ACTININ; BIOLOGICAL MARKER; PLANT MEDICINAL PRODUCT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ACTIVITY; CELL COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFICACY; EMBRYOTOXICITY; FIRST TRIMESTER PREGNANCY; GINGER; GINKGO BILOBA; GINSENG; HEART MUSCLE CELL; IMMUNOCYTOCHEMISTRY; MOUSE; MOUSE EMBRYONIC STEM CELL; MUSCLE CELL; NONHUMAN; PROTEIN CONTENT; PROTEIN LOCALIZATION; SARCOMERE; ANIMAL; CARDIAC MUSCLE CELL; CELL CULTURE; CELL SURVIVAL; CHICK EMBRYO; DOSE RESPONSE; DRUG EFFECTS; EMBRYOLOGY; EMBRYONIC STEM CELL; HEART; HEART CONTRACTION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RISK ASSESSMENT;

ACTININ; ANIMALS; BIOMARKERS; CELL SURVIVAL; CELLS, CULTURED; CHICK EMBRYO; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBRYONIC STEM CELLS; HEART; MICE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PLANT PREPARATIONS; RISK ASSESSMENT;

EID: 84957795536     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2015.12.003     Document Type: Article

References (72)

1. Hoffman J.I., Kaplan S. The incidence of congenital heart disease. J. Am. Coll. Cardiol. 2002, 39(12):1890-1900.
2. Jenkins K.J., et al. Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association council on cardiovascular disease in the young: endorsed by the American Academy of Pediatrics. Circulation 2007, 115(23):2995-3014.
3. Mahler G.J., Butcher J.T. Cardiac developmental toxicity. Birth Defects Res. C Embryo Today 2011, 93(4):291-297.
4. Parsons J.F., Rockley J., Richold M. In vitro micromass teratogen test: interpretation of results from a blind trial of 25 compounds using three separate criteria. Toxicol. In Vitro 1990, 4(4-5):609-611.
5. Pratten M., et al. Primary cell and micromass culture in assessing developmental toxicity. Methods Mol. Biol. 2012, 889:115-146.
6. Hurst H.S., Clothier R.H., Pratten M. An evaluation of a novel chick cardiomyocyte micromass culture assay with two teratogens/embryotoxins associated with heart defects. Altern. Lab. Anim. 2007, 35(5):505-514.
7. Chen M., et al. Enrichment of cardiac differentiation of mouse embryonic stem cells by optimizing the hanging drop method. Biotechnol. Lett. 2011, 33(4):853-858.
8. Tovar R.T., Petzel R.M. Herbal toxicity. Dis. Mon. 2009, 55(10):592-641.
9. Belew C. Herbs and the childbearing woman guidelines for midwives. J. Nurse-Midwifery 1999, 44(3):231-252.
10. Xue C.C., et al. Complementary and alternative medicine use in Australia: a national population-based survey. J. Altern. Complement. Med. 2007, 13(6):643-650.
11. Hall H.G., Griffiths D.L., McKenna L.G. The use of complementary and alternative medicine by pregnant women: a literature review. Midwifery 2011, 27(6):817-824.
12. Talpur A.D., Ikhwanuddin M., Ambok Bolong A.-M. Nutritional effects of ginger (Zingiber officinale Roscoe) on immune response of Asian sea bass Lates calcarifer (Bloch) and disease resistance against Vibrio harveyi. Aquaculture 2013, 400-401:46-52.
13. Tiran D. Ginger to reduce nausea and vomiting during pregnancy: evidence of effectiveness is not the same as proof of safety. Complement. Ther. Clin. Pract. 2012, 18(1):22-25.
14. Viljoen E., et al. A systematic review and meta- analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting. Nutr. J. 2014, 13:20.
15. Wang S., et al. Biological properties of 6-gingerol: a brief review. Nat. Prod. Commun. 2014, 9(7):1027-1030.
16. Ali B.H., et al. Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research. Food Chem. Toxicol. 2008, 46(2):409-420.
17. Yu Y., et al. Examination of the pharmacokinetics of active ingredients of ginger in humans. AAPS J. 2011, 13(3):417-426.
18. Jiang S.Z., Wang N.S., Mi S.Q. Plasma pharmacokinetics and tissue distribution of [6]-gingerol in rats. Biopharm. Drug Dispos. 2008, 29(9):529-537.
19. Kim E.C., et al. [6]-Gingerol, a pungent ingredient of ginger, inhibits angiogenesis in vitro and in vivo. Biochem. Biophys. Res. Commun. 2005, 335(2):300-308.
20. Susan E. Apoptosis: a review of programmed cell death. Toxicol. Pathol. 2007, 35(4):495-516.
21. Chakraborty D., et al. [6]-Gingerol induces caspase 3 dependent apoptosis and autophagy in cancer cells: drug-DNA interaction and expression of certain signal genes in HeLa cells. Eur. J. Pharmacol. 2012, 694(1-3):20-29.
22. Yang G., et al. Genotoxic effect of 6-gingerol on human hepatoma G2 cells. Chem. Biol. Interact. 2010, 185(1):12-17.
23. Lee H.S., et al. [6]-Gingerol inhibits metastasis of MDA-MB-231 human breast cancer cells. J. Nutr. Biochem. 2008, 19(5):313-319.
24. Lin C.B., Lin C.C., Tsay G.J. 6-Gingerol inhibits growth of colon cancer cell loVo via induction of G2/M arrest. Evid. Based Complement. Alternat. Med. 2012, 2012:326096.
25. Heitmann K., Nordeng H., Holst L. Safety of ginger use in pregnancy: results from a large population-based cohort study. Eur. J. Clin. Pharmacol. 2013, 69(2):269-277.
26. Portnoi G., et al. Prospective comparative study of the safety and effectiveness of ginger for the treatment of nausea and vomiting in pregnancy. Am. J. Obstet. Gynecol. 2003, 189(5):1374-1377.
27. Zhou Z., Zheng S. The missing link in Ginkgo evolution. Nature 2003, 423(6942):821-822.
28. Zehra U., Tahir M., Lone K.P. Ginkgo biloba induced malformations in mice. J. Coll. Phys. Surg. Pak. 2010, 20(2):117-121.
29. Chan W.H. Ginkgolides induce apoptosis and decrease cell numbers in mouse blastocysts. Biochem. Biophys. Res. Commun. 2005, 338(2):1263-1267.
30. Shiao N.H., Chan W.H. Injury effects of ginkgolide B on maturation of mouse oocytes, fertilization, and fetal development in vitro and in vivo. Toxicol. Lett. 2009, 188(1):63-69.
31. Luo Y., et al. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc. Natl. Acad. Sci. U. S. A 2002, 99(19):12197-12202.
32. Kim K.S., et al. Ginkgo biloba extract (EGb 761) induces apoptosis by the activation of caspase-3 in oral cavity cancer cells. Oral. Oncol. 2005, 41(4):383-389.
33. Hsuuw Y.D., et al. Ginkgolide B induces apoptosis via activation of JNK and p21-activated protein kinase 2 in mouse embryonic stem cells. Ann. N. Y. Acad. Sci. 2009, 1171:501-508.
34. Chan W.H. Ginkgolide B induces apoptosis and developmental injury in mouse embryonic stem cells and blastocysts. Hum. Reprod. 2006, 21(11):2985-2995.
35. Pinto R.M., et al. Intra-uterine growth retardation after prenatal administration of Ginkgo biloba to rats. Reprod. Toxicol. 2007, 23(4):480-485.
36. Sierpina V.S., Wollschlaeger B., Blumenthal M. Ginkgo biloba. Am. Fam. Phys. 2003, 68(5):923-926.
37. Organization, W.H., Folium Ginkgo. 1999: Geneva p. 154-67.
38. Leung K.W. Ginseng and male reproductive function. Spermatogenesis 2013, 3(3):e26391.
39. Baeg I.-H., So S.-H. The world ginseng market and the ginseng (Korea). J. Ginseng Res. 2013, 37(1):1-7.
40. Poindexter B.J., et al. Ginseng: cardiotonic in adult rat cardiomyocytes, cardiotoxic in neonatal rat cardiomyocytes. Life Sci. 2006, 79(25):2337-2344.
41. Jiang R., et al. Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3. Br. J. Pharmacol. 2015, 172(4):1059-1073.
42. Xie C.L., et al. A systematic review and meta- analysis of Ginsenoside-Rg1 (G-Rg1) in experimental ischemic stroke. Sci. Rep. 2015, 5:7790.
43. Lu J.M., Yao Q., Chen C. Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr. Vasc. Pharmacol. 2009, 7(3):293-302.
44. Karmazyn M., Moey M., Gan X.T. Therapeutic potential of ginseng in the management of cardiovascular disorders. Drugs 2011, 71(15):1989-2008.
45. Liu P., et al. Effects of ginsenoside Rg1 on postimplantation rat and mouse embryos cultured in vitro. Toxicol. In Vitro 2006, 20(2):234-238.
46. Tsutomu O., Hisayuki T., Yoshio T. Studies on absorption, distribution, excretion and metabolism of Ginseng Saponins II. The Absorption distribution, excretion of ginsenoside Rg1 in the rat. Chem. Pharm. Bull. 1982, 31(1):292-298.
47. Woelkart K., et al. Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. Phytother. Res. 2010, 24(3):445-450.
48. Zick S.M., et al. Pharmacokinetics of 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol and conjugate metabolites in healthy human subjects. Cancer Epidemiol. Biomarkers Prev. 2008, 17(8):1930-1936.
49. Feng L., et al. Pharmacokinetics, tissue distribution, metabolism, and excretion of ginsenoside Rg1 in rats. Arch. Pharm. Res. 2010, 33(12):1975-1984.
50. Flint O.P., Orton T.C. An in vitro assay for teratogens with cultures of rat embryo midbrain and limb bud cells. Toxicol. Appl. Pharmacol. 1984, 76(2):383-395.
51. Hurst H., Clothier R.H., Pratten M. An evaluation of the chick cardiomyocyte micromass system for identification of teratogens in a blind trial. Reprod. Toxicol. 2009, 28(4):503-510.
52. Memon S., Pratten M.K. Developmental toxicity of ethanol in chick heart in ovo and in micromass culture can be prevented by addition of vitamin C and folic acid. Reprod. Toxicol. 2009, 28(2):262-269.
53. Ahir B.K., Pratten M.K. Association of anxiolytic drugs diazepam and lorazepam, and the antiepileptic valproate, with heart defects-effects on cardiomyocytes in micromass (MM) and embryonic stem cell culture. Reprod. Toxicol. 2011, 31(1):66-74.
54. Memon S., Pratten M.K. Teratogenic effects of diabetic conditions in chick heart in ovo and in micromass culture may be prevented by addition of vitamin C and folic acid. Reprod. Toxicol. 2013, 35:117-124.
55. Shaikh Qureshi W.M., et al. Evaluation of bupropion hydrochloride developmental cardiotoxic effects in chick cardiomyocyte micromass culture and stem cell derived cardiomyocyte systems. Birth Defects Res. B Dev. Reprod. Toxicol. 2014, 101(5):371-378.
56. Page B., Page M., Noel C. A new fluorometric assay for cytotoxicity measurements in-vitro. Int. J. Oncol. 1993, 3(3):473-476.
57. Putnam K.P., Bombick D.W., Doolittle D.J. Evaluation of eight in vitro assays for assessing the cytotoxicity of cigarette smoke condensate. Toxicol. In Vitro 2002, 16(5):599-607.
58. Klepser T.B., et al. Assessment of patients' perceptions and beliefs regarding herbal therapies. Pharmacotherapy 2000, 20:1.
59. Young H.Y., et al. Analgesic and anti-inflammatory activities of [6]-gingerol. J. Ethnopharmacol. 2005, 96(1-2):207-210.
60. Sanwal S.K., et al. Antioxidant phytochemicals and gingerol content in diploid and tetraploid clones of ginger (Zingiber officinale Roscoe). Sci. Hortic. 2010, 124(2):280-285.
61. Pertz H.H., et al. Effects of ginger constituents on the gastrointestinal tract: role of cholinergic M3 and serotonergic 5-HT3 and 5-HT4 receptors. Planta Med. 2011, 77(10):973-978.
62. Nigam N., et al. [6]-Gingerol induces reactive oxygen species regulated mitochondrial cell death pathway in human epidermoid carcinoma A431 cells. Chem. Biol. Interact. 2009, 181(1):77-84.
63. Lee T.Y., et al. 6-Gingerol inhibits ROS and iNOS through the suppression of PKC-alpha and NF-kappaB pathways in lipopolysaccharide- stimulated mouse macrophages. Biochem. Biophys. Res. Commun. 2009, 382(1):134-139.
64. Park S.A., et al. Effect of [6]-gingerol on myofibroblast differentiation in transforming growth factor beta 1-induced nasal polyp- derived fibroblasts. Am. J. Rhinol. Allergy 2012, 26(2):97-103.
65. Chen S.H., et al. Protective effects of Ginkgo biloba extract on the ethanol-induced gastric ulcer in rats. World J. Gastroenterol. 2005, 11(24):3746-3750.
66. Wang X., et al. Neuroprotection against permanent focal cerebral ischemia by ginkgolides A and B is associated with obstruction of the mitochondrial apoptotic pathway via inhibition of c-Jun N-terminal kinase in rats. J. Neurosci. Res. 2014, 92(2):232-242.
67. Xia S.-h., Fang D.-c. Pharmacological action and mechanisms of ginkgolide B. Chin. Med. J. 2007, 120(10):922-928.
68. Radad K., et al. Ginsenosides Rb1 and Rg1 effects on survival and neurite growth of MPP + -affected mesencephalic dopaminergic cells. J. Neural. Transm. 2004, 111(1):37-45.
69. Park E.K., et al. Ginsenoside Rh2 reduces ischemic brain injury in rats. Biol. Pharm. Bull. 2004, 27(3):433-436.
70. Ji Y.C., et al. Neuroprotective effect of ginseng total saponins in experimental traumatic brain injury. J. Korean Med. Sci. 2005, 20(2):291-296.
71. Wang J., et al. Antidepressant-like effects of the active acidic polysaccharide portion of ginseng in mice. J. Ethnopharmacol. 2010, 132(1):65-69.
72. Shin S., et al. Korean red ginseng extract does not cause embryo-fetal death or abnormalities in mice. Birth Defects Res. B Dev. Reprod. Toxicol. 2010, 89(1):78-85.